Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy.

about

Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy.

Item

http://www.wikidata.org/entity/Q47109507

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Spotlight on olaratumab in the ...... lopment, and place in therapy.

@en

Spotlight on olaratumab in the ...... lopment, and place in therapy.

@nl

type

Item

label

Spotlight on olaratumab in the ...... lopment, and place in therapy.

@en

Spotlight on olaratumab in the ...... lopment, and place in therapy.

@nl

prefLabel

Spotlight on olaratumab in the ...... lopment, and place in therapy.

@en

Spotlight on olaratumab in the ...... lopment, and place in therapy.

@nl

P1476

Spotlight on olaratumab in the ...... lopment, and place in therapy.

@en

P2093

Elizabeth J Davis

http://www.w3.org/2001/XMLSchema#string

Rashmi Chugh

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

Cancer statistics, 2016

Role of platelet-derived growth factors in physiology and medicine

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

P304

3579-3587

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2147/DDDT.S121298

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2017-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29263653

http://www.w3.org/2001/XMLSchema#string

P921

biomedical investigative technique

P932

5732568

http://www.w3.org/2001/XMLSchema#string